Skip to content

Arvinas ARVN Proceeds from issuance of common stock and pre-funded warrants

Proceeds from issuance of common stock and pre-funded warrants at other companies

Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$0
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$0-100%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$81.01M-28.0%
Energy Fuels logo
Energy FuelsUUUU
$68.05M+1,538%
Esperion Therapeutics logo
Esperion TherapeuticsESPR
$18.15M-19.9%
SELLAS Life Sciences Group, Inc. logo
SELLAS Life Sciences Group, Inc.SLS
$0-100%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept arvn:ProceedsFromIssuanceOfCommonStockAndWarrants.

The official record: Arvinas’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's proceeds from issuance of common stock and pre-funded warrants.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's proceeds from issuance of common stock and pre-funded warrants?
Arvinas (ARVN) reported proceeds from issuance of common stock and pre-funded warrants of $0 in Q4 2025.
What is the long-term trend for Arvinas's proceeds from issuance of common stock and pre-funded warrants?
Over 4 years (2021 to 2025), Arvinas's proceeds from issuance of common stock and pre-funded warrants has grown at a -100.0% compound annual growth rate (CAGR), from $264.6M to $0.
What does proceeds from issuance of common stock and pre-funded warrants mean?
This represents the cash inflows received by the company from the sale of common equity shares or the exercise of pre-funded warrants. It serves as a primary indicator of external equity financing activities used to fund operations, research and development, or capital expenditures. This metric is critical for evaluating the company's reliance on capital markets and the potential dilution impact on existing shareholders.